Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome

Aubert, H.; Frère, Corinne; Aillaud, M F; Morange, Pierre‐Emmanuel; Juhan‐Vague, I.; Alessi, Marie‐Christine

doi:10.1046/j.1538-7836.2003.00147.x

Cited by 54 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, the WHO definition uses body mass index (BMI) to estimate intra-abdominal obesity; this measure does not reliably reflect visceral adipose tissue in various populations, including most Asians [25]. This distinction is important because studies have ** Significant insulin resistance defined as absolute value of insulin resistance (HOMA-IR) C 2.5 [7] *** Difference in proportion between cases and controls significant at 5 % level demonstrated a higher concentration of adipose-related, deleterious free fatty acids (FFAs) en route to the liver by way of the splanchnic circulation in patients with demonstrated increased visceral fat relative to those with higher subcutaneous fat [26]. Thus waist circumference in preference to BMI had been used as a parameter for diagnosis of MS.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Insulin Resistance and Metabolic Syndrome in Drug Naive Patients of Bipolar Disorder

et al. 2013

View full text Add to dashboard Cite

The levels of fasting glucose, fasting insulin, insulin resistance (IR) and the prevalence of metabolic syndrome (MS) in a sample population of bipolar disorder (BPD) patients who were newly diagnosed and psychotropically naïve were assessed and compared with an age, sex and racially matched control population. 55 BPD-I patients (15-65 years) who were non-diabetic, nonpregnant, and drug naïve for a period of at least 6 months were included in the study. Diagnosis was made using the structured clinical interview for DSM-IV axis I disorders (SCID IV). IR was assessed using homeostasis model of insulin resistance (HOMA-IR); MS was defined according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III). Data were compared with 25 healthy controls. BPD patients had significantly higher mean levels of fasting plasma insulin (13.2 ± 9.2 vs. 4.68 ± 3.1 lIU/ ml, p \ 0.05), postprandial plasma insulin (27.2 ± 14.5 vs. 18.1 ± 9.3 lIU/ml, p \ 0.05) and a higher value of HOMA-IR (3.16 ± 2.2 vs. 1.19 ± 0.8, p \ 0.05) when compared to the controls. A significantly higher proportion of patients of BPD compared to controls were manifesting levels of fasting plasma glucose, serum triglyceride and blood pressure higher than the cut off while waist circumference and serum HDL cholesterol failed to show any significant difference in the proportion. There was a significantly higher proportion of prevalence of IR between BPD cases and controls (26/55 vs. 2/25, z value 9.97, p \ 0.05) while there was no significant difference in proportion of prevalence of MS between these two groups. Within BPD patients, logistic regression analysis showed that age, sex or current mood status (depressed/ manic) were not significantly predictive of presence or absence of MS or increased IR.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Insulin Resistance and Metabolic Syndrome in Drug Naive Patients of Bipolar Disorder

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This suggested that like PAI-1, TAFI may be a component of the MS. However, another study (13) found only nonindependent association between plasma TAFI and components of MS in obese subjects. In the present study, we also could not find any significant associations between plasma TAFI and components of the MS, such as BMI, triglyceride, and HDL cholesterol, in type 2 diabetic patients.…”

Section: Measurementsmentioning

confidence: 91%

“…In a previous study of patients with type 2 diabetes (12), plasma TAFI correlated independently with components of the MS including visceral fat and the glucose infusion rate, an index of insulin resistance. However, Aubert et al (13) ar-gued that plasma TAFI shows only a weak, nonindependent correlation with insulin resistance. Thus, the identity of main determinants of plasma TAFI concentrations remains unclear.…”

mentioning

confidence: 99%

Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

OBJECTIVE -To determine whether plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with type 2 diabetes were associated with components of metabolic syndrome (MS), including high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI)-1, and LDL cholesterol.RESEARCH DESIGN AND METHODS -We studied 136 consecutive patients with type 2 diabetes. Diagnosis of MS was diagnosed by current criteria. Hypercholesterolemia (HC) was defined as serum LDL cholesterol Ͼ140 mg/dl (3.6 mmol/l) or treatment with a statin. For comparisons, diabetic patients were divided into four groups: those with no MS and no HC (n ϭ 38), with MS but not HC (n ϭ 39), with no MS but with HC (n ϭ 26), and with both MS and HC (n ϭ 33).RESULTS -Considering all patients with type 2 diabetes, plasma PAI-1 was strongly associated with MS components such as BMI, triglyceride, alanine aminotransferase, a homeostasis model assessment of insulin resistance, and hs-CRP. Plasma TAFI only correlated positively and independently with LDL cholesterol. Plasma concentrations of plasmin-␣2-antiplasmin complex (PAP), a measure of fibrinolytic activity in blood, showed a significant negative correlation with plasma PAI-1 but not TAFI. Diabetic patients with both MS and HC had the highest serum hs-CRP concentrations and the lowest plasma PAP concentrations.CONCLUSIONS -LDL cholesterol is a main determinant of plasma TAFI in patients with type 2 diabetes. Coexistence of MS and HC synergistically accelerates inflammation and impairment of fibrinolysis via elevated concentrations of both TAFI and PAI-1, which inhibit fibrinolysis. Diabetes Care 28:2211-2216, 2005M etabolic syndrome (MS), also known as insulin resistance syndrome, is defined by the clustering of several cardiovascular risk factors in an individual patient, including impaired glucose tolerance (diabetes), hypertension, dyslipidemia, and visceral obesity (1,2). Several studies have demonstrated that this syndrome strongly predicts cardiovascular disease (CVD), especially coronary heart disease (3,4), independently of LDL cholesterol. Recently, a close association of MS with hemostatic abnormalities has been reported. Among hemostatic abnormalities, an increase in plasma plasminogen activator inhibitor (PAI)-1, a strong inhibitor of fibrinolysis, is considered a core feature of MS (5). High plasma PAI-1 concentrations may be associated with thrombus formation, causing cardiovascular events (6).A new inhibitor of fibrinolysis has been recently identified in plasma. As this protein is activated by thrombin and then downregulates fibrinolysis, it has been named thrombin-activatable fibrinolysis inhibitor (TAFI) (7). TAFI proved to be identical with plasma procarboxypeptidase B, U, or R (8). TAFI removes COOHterminal lysine or arginine residues from partially degraded fibrin, decreasing plasminogen binding to the fibrin surface (9). Since TAFI is associated with coagulation/ fibrinolysis and inflammation, plasma TAFI may participate in arterial thromb...

show abstract

“…intercellular adhesion molecule-1, P-selectin, and E-selectin) than those without the syndrome (142)(143)(144)(145). Moreover, increased endothelial cell microparticles (EMP) release, platelet and leukocyte hyperactivation, increased binding of both EMPs and platelets to leukocytes are also shown in patients with the metabolic syndrome (133,146).…”

Section: Hypercoagulability and Hypofibrinolysismentioning

confidence: 99%

Hemostatic abnormalities in endocrine and metabolic disorders

Franchini¹,

Lippi²,

Manzato³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

The hemostatic balance is a complex system where the delicate equilibrium is regulated by several factors, including hormones. This review summarizes current knowledge of the effects of most frequent endocrine and metabolic diseases (such as hypothyroidism, hyperthyroidism, Cushing's syndrome, GH-related pituitary dysfunctions, pituitary prolactin-producing adenomas, polycystic ovary syndrome, primary hyperparathyroidism, and metabolic syndrome) on coagulation and fibrinolysis. Overt hypothyroidism appears to be associated with a bleeding tendency, whereas all other endocrine diseases appear to be associated with a thrombotic tendency. Globally, the disorders of coagulation and fibrinolysis usually range from mild to moderate, and, rarely, to severe laboratory abnormalities (for example, bleeding diathesis in overt hypothyroidism mainly due to an acquired von Willebrand's disease type 1). Further larger and high-quality studies are needed to provide more definitive information on the effects of endocrine disorders on coagulation and fibrinolysis.

show abstract

Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome

Cited by 54 publications

References 25 publications

Assessment of Insulin Resistance and Metabolic Syndrome in Drug Naive Patients of Bipolar Disorder

Assessment of Insulin Resistance and Metabolic Syndrome in Drug Naive Patients of Bipolar Disorder

Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes

Hemostatic abnormalities in endocrine and metabolic disorders

Contact Info

Product

Resources

About